Drugs / Me1-14 F(ab')2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00002754 | Feb 1993 → Apr 2001 | central nervous system neoplasm, cutaneous melanoma, metastatic malignant neoplasm | Duke University | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00002751 | Jul 1989 → May 2004 | metastatic malignant neoplasm | Duke University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Me1-14 F(ab')2 | “monoclonal antibody Me1-14 F(ab')2” NCT00002754 ↗ |
| Known as | 131I-Me1-14 F(ab')2 | “Iodine-131-Labeled Monoclonal Antibody Fragment Me1-14 F(ab')2, 131I-Me1-14 F(ab')2.” NCT00002751 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody Me1-14 F(ab')2” NCT00002751 ↗ |
| Route | Intrathecal | “131-iodine-labeled monoclonal antibody fragment Me1-14 F(ab')2 administered intrathecally” NCT00002751 ↗ |